AsymBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), is thrilled to extend our warmest congratulations to Novacyte Therapeutics on the FDA's recent clearance of their Investigational New Drug (IND) application for NC18 (HER2-ADC). This milestone achievement underscores Novacyte's dedication to driving innovation in ADC development.
At AsymBio, we are proud to stand alongside Novacyte as a trusted partner in advancing this groundbreaking project. We look forward to continuing our collaboration to bring impactful ADC/NDC solutions to patients worldwide.
For more information about AsymBio and its comprehensive biologics CDMO services, visit www.asymbio.com